Cecilia Qi – Chief Executive Officer, DCH Auriga
Drawing on over two decades of leadership industry across Asia, Cecilia Qi reflects her transition from global pharma to leading DCH Auriga. She shares insights on the company’s evolution into…
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Disease and Respiratory. We are also selectively active in the areas of autoimmunity, neuroscience and infection. Its presence in Hong Kong – in the name of AstraZeneca Hong Kong – can be traced back to 1999 when AstraZeneca was formed following a merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Both companies were established in Hong Kong in the 1970s.
AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since our establishment, we have been focusing on identifying and bringing in the latest medical solutions as well as seeking ongoing business development. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
Contact
Address: Unit 1-3, 11/F, 18 King Wah Road, North Point
Tel: +(852) 2420 7388
Website: https://www.astrazeneca.com/country-sites/hong-kong.html
Drawing on over two decades of leadership industry across Asia, Cecilia Qi reflects her transition from global pharma to leading DCH Auriga. She shares insights on the company’s evolution into…
CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and…
At Hong Kong Children’s Hospital (HKCH), a new chapter in rare disease medicine is unfolding. Under the leadership of Dr Luk Ho-ming, Chief of Service of the Department of Clinical…
Established in 2018 under the Hospital Authority, the Hong Kong Children’s Hospital (HKCH) has rapidly emerged as the city’s leading centre for complex paediatric and rare-disease care. Bringing together advanced…
Hong Kong is entering a pivotal new chapter in its healthcare and regulatory evolution. Under the leadership of Secretary for Health Professor Lo Chung-mau, the city is reshaping its position…
GSK Hong Kong’s first year under Nicholas Teo marks a period of rapid evolution in the city’s healthcare system, from the strengthening of primary care to a deeper reliance on…
With a strong heritage in Asia, DKSH has evolved into a leading force in connecting global healthcare innovation with local patient access. In this interview, Wai Ting Fong, VP Healthcare…
With a career spanning clinical medicine, hospital management, and healthcare policy, Dr Kenneth Tsang brings a rare depth of perspective to his dual role as Regional CEO of IHH Healthcare…
Since our last conversation with Tony Cheng in mid-2024, Merck Hong Kong has entered a new phase of consolidation and growth. The affiliate has strengthened its team, accelerated its adoption…
With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city,…
At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper,…
In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team…
See our Cookie Privacy Policy Here
